Ablation with low-dose radioiodine and thyrotropin alfa in thyroid cancer

New England Journal of Medicine

Volumn 366, Issue 18, 2012, Pages 1674-1685

  Mallick, Ujjal ^a   Harmer, Clive ^o   Yap, Beng ^b   Wadsley, Jonathan ^c   Clarke, Susan ^k   Moss, Laura ^d   Nicol, Alice ^f   Clark, Penelope M ^g   Farnell, Kate ⁱ   McCready, Ralph ^j   Smellie, James ^l   Franklyn, Jayne A ^h   John, Rhys ^e   Nutting, Christopher M ⁿ   Newbold, Kate ^o   Lemon, Catherine ^p   Gerrard, Georgina ^q   Abdel Hamid, Abdel ^r   Hardman, John ^s   Macias, Elena ^t   Roques, Tom ^u   Whitaker, Stephen ^v   Vijayan, Rengarajan ^w   Alvarez, Pablo ^m   Beare, Sandy ^m   Forsyth, Sharon ^m   Kadalayil, Latha ^m   Hackshaw, Allan ^m   more..

^a FREEMAN HOSPITAL   (United Kingdom)

^b CHRISTIE HOSPITAL   (United Kingdom)

^c WESTON PARK HOSPITAL   (United Kingdom)

^d VELINDRE CANCER CENTRE   (United Kingdom)

^e UNIVERSITY HOSPITAL OF WALES   (United Kingdom)

^f SOUTHERN GENERAL HOSPITAL   (United Kingdom)

^g UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

^h UNIVERSITY OF BIRMINGHAM   (United Kingdom)

ⁱ Butterfly Cancer Trust UK   (United Kingdom)

^j Worthing Hospital   (United Kingdom)

^k GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^l CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

^m UNIVERSITY COLLEGE LONDON   (United Kingdom)

ⁿ INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^o ROYAL MARSDEN HOSPITAL   (United Kingdom)

^p MOUNT VERNON HOSPITAL   (United Kingdom)

^q United Kingdom   (United Kingdom)

^r CASTLE HILL HOSPITAL   (United Kingdom)

^s JAMES COOK UNIVERSITY HOSPITAL   (United Kingdom)

^t EAST KENT HOSPITALS UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

^u NORFOLK AND NORWICH UNIVERSITY HOSPITAL   (United Kingdom)

^v ROYAL SURREY COUNTY HOSPITAL   (United Kingdom)

^w ROYAL DERBY HOSPITAL   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

RADIOACTIVE IODINE; RECOMBINANT THYROTROPIN; THYROID HORMONE;

ABLATION THERAPY; ACUTE KIDNEY FAILURE; ADULT; ARTICLE; CANCER STAGING; CONTROLLED STUDY; DISEASE ASSOCIATION; DOSE RESPONSE; DOSIMETRY; DRUG COST; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HEMATEMESIS; HUMAN; LENGTH OF STAY; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; NECK PAIN; OUTCOME ASSESSMENT; PELVIS PAIN SYNDROME; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; RISK FACTOR; SPINE FRACTURE; THORAX PAIN; THYROID CANCER; UNSPECIFIED SIDE EFFECT;

EID: 84860433135     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1109589     Document Type: Article

References (41)

1. Cancer Research UK. Thyroid cancer statistics - UK (http://info.cancer researchuk.org/cancerstats/types/thyroid).
2. National Cancer Institute. Thyroid cancer (http://www.cancer.gov/ cancertopics/types/thyroid).
3. Sawka AM, Thephamongkhol K, Brouwers M, Thabane L, Browman G, Gerstein HC. Clinical review 170: a systematic review and metaanalysis of the effectiveness of radioactive iodine remnant ablation for well-differentiated thyroid cancer. J Clin Endocrinol Metab 2004;89:3668-76. (Pubitemid 39089119)
4. Sawka AM, Brierley JD, Tsang RW, et al. An updated systematic review and commentary examining the effectiveness of radioactive iodine remnant ablation in well-differentiated thyroid cancer. Endocrinol Metab Clin North Am 2008;37:457-80. (Pubitemid 351711675)
5. Mazzaferri EL, Kloos RT. Current approaches to primary therapy for papillary and follicular thyroid cancer. J Clin Endocrinol Metab 2001;86:1447-63. (Pubitemid 32374886)
6. 131I) in patients with papillary and follicular thyroid cancer and the issue of remnant ablation: a consensus report. Eur J Endocrinol 2005;153:651-9.
7. Verburg FA, de Keizer B, Lips CJM, Zelissen PMJ, de Klerk JMH. Prognostic significance of successful ablation with radioiodine of differentiated thyroid cancer patients. Eur J Endocrinol 2005;152: 33-7. (Pubitemid 40185450)
8. 131I activity for remnant ablation in patients with differentiated thyroid cancer: a systematic review. J Clin Endocrinol Metab 2007;92:28-38.
9. British Thyroid Association. Guidelines for the management of thyroid cancer: second edition. London: Royal College of Physicians, 2007 (http://www.british-thyroid-association.org/news/Docs/Thyroid-cancer-guidelines- 2007.pdf).
10. Tuttle RM, Ball DW, Byrd D, et al. Thyroid carcinoma. J Natl Compr Canc Netw 2010;8:1228-74.
11. Cooper DS, Doherty GM, Haugen BR, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2009;19:1167-214. [Erratum, Thyroid 2010;20:674-5.]
12. Pacini F, Schlumberger M, Dralle H, Elisei R, Smit JW, Wiersinga W. European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol 2006;154:787-803. [Erratum, Eur J Endocrinol 2006;155:385.] (Pubitemid 43997716)
13. Rubino C, de Vathaire F, Dottorini ME, et al. Second primary malignancies in thyroid cancer patients. Br J Cancer 2003; 89:1638-44. (Pubitemid 37464133)
14. Iyer NG, Morris LG, Tuttle RM, Shaha AR, Ganly I. Rising incidence of second cancers in patients with low-risk (T1N0) thyroid cancer who receive radioactive iodine therapy. Cancer 2011;117:4439-46.
15. 99m) Tc-pertechnetate scintigraphy predicts radioiodine ablation effectiveness in patients with differentiated thyroid carcinoma. Head Neck 2011;33:552-6.
16. Spencer CA, Takeuchi M, Kazarosyan M, et al. Serum thyroglobulin autoantibodies: prevalence, influence on serum thyroglobulin measurement and prognostic significance in patients with differentiated thyroid carcinoma. J Clin Endocrinol Metab 1998;83:1121-7. (Pubitemid 28496379)
17. QualityMetric. SF-36v2 health survey (http://www.qualitymetric.com/ WhatWeDo/GenericHealthSurveys/SF36v2HealthSurvey/tabid/185/Default.aspx).
18. Mazzaferri EL, Robbins RJ, Spencer CA, et al. A consensus report of the role of serum thyroglobulin as a monitoring method for low-risk patients with papillary thyroid carcinoma. J Clin Endocrinol Metab 2003;88:1433-41. (Pubitemid 36623351)
19. Pacini F, Ladenson PW, Schlumberger M, et al. Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin in differentiated thyroid carcinoma: results of an international, randomized, controlled study. J Clin Endocrinol Metab 2006;91:926-32. (Pubitemid 43357760)
20. Cancer Therapy Evaluation Program. Common Terminology Criteria for Adverse Events (CTCAE), version 3.0 (http://www.acrin.org/Portals/0/Protocols/ common/resources/CTCAEv3.pdf).
21. Lim DJ, O JH, Kim MH, et al. Clinical significance of observation without repeated radioiodine therapy in differentiated thyroid carcinoma patients with positive surveillance whole-body scans and negative thyroglobulin. Korean J Intern Med 2010;25:408-14.
22. Pacini F, Agate L, Elisei R, et al. Outcome of differentiated thyroid cancer with detectable serum Tg and negative diagnostic (13I)I whole body scan: comparison of patients treated with high (131)I activities versus untreated patients. J Clin Endocrinol Metab 2001;86:4092-7. (Pubitemid 32848518)
23. Barbaro D, Verburg FA, Luster M, Reiners C, Rubello D. ALARA in rhTSH-stimulated post-surgical thyroid remnant ablation: what is the lowest reasonably achievable activity? Eur J Nucl Med Mol Imaging 2010;37:1251-4.
24. Molinaro E, Viola D, Passannanti P, et al. Recombinant human TSH (rhTSH) in 2009: new perspectives in diagnosis and therapy. Q J Nucl Med Mol Imaging 2009; 53:490-502.
25. Kloos RT. Survey of radioiodine therapy safety practices highlights the need for user-friendly recommendations. Thyroid 2011;21:97-9.
26. Willegaignon J, Sapienza M, Ono C, et al. Outpatient radioiodine therapy for thyroid cancer: a safe nuclear medicine procedure. Clin Nucl Med 2011;36:440-5.
27. Globocan 2008. Most frequent cancers: men (http://globocan.iarc.fr/ factsheets/populations/factsheet.asp?uno=900).
28. Davies L, Welch HG. Increasing incidence of thyroid cancer in the United States, 1973-2002. JAMA 2006;295:2164-7.
29. Cramer JD, Fu P, Harth KC, Margevicius S, Wilhelm SM. Analysis of the rising incidence of thyroid cancer using the Surveillance, Epidemiology and End Results national cancer data registry. Surgery 2010; 148:1147-52.
30. Brassard M, Borget I, Edet-Sanson A, et al. Long-term follow-up of patients with papillary and follicular thyroid cancer: a prospective study on 715 patients. J Clin Endocrinol Metab 2011;96:1352-9.
31. Powell C, Welsh L, Haq M, et al. Excellent long-term outcome following 1.1 GBq radioiodine remnant ablation for differentiated thyroid cancer. Presented at the European Thyroid Association 35th Annual Meeting, Krakow, Poland, September 10-14, 2011:P126. abstract.
32. Tamilia M, Al-Kahtani N, Rochon L, et al. Serum thyroglobulin predicts thyroid remnant ablation failure with 30 mCi iodine-131 treatment in patients with papillary thyroid carcinoma. Nucl Med Commun 2011;32:212-20.
33. Salvatori M, Perotti G, Giovanella L, Dottorini ME. Can an undetectable value of TG and a negative neck ultrasound study be considered reliable methods to assess the completeness of thyroid ablation? Eur J Nucl Med Mol Imaging 2010; 37:1039-40.
34. Tala Jury HP, Castagna MG, Fioravanti C, Cipri C, Brianzoni E, Pacini F. Lack of association between urinary iodine excretion and successful thyroid ablation in thyroid cancer patients. J Clin Endocrinol Metab 2010;95:230-7.
35. Catargi B, Borget I, Deandreis D, et al. Comparison of four strategies of radioiodine ablation in patients with thyroid cancer with low-risk of recurrence: the randomized, prospective ESTIMABL study. Presented at the 14th International Thyroid Congress, Paris, September 11-16, 2010. abstract.
36. Mäenpää HO, Heikkonen J, Vaalavirta L, Tenhunen M, Joensuu H. Low vs. high radioiodine activity to ablate the thyroid after thyroidectomy for cancer: a randomized study. PLoS One 2008;3(4):e1885.
37. Kukulska A, Krajewska J, Gawkowska-Suwińska M, et al. Radioiodine thyroid remnant ablation in patients with differentiated thyroid carcinoma (DTC): prospective comparison of long-term outcomes of treatment with 30, 60, and 100 mCi. Thyroid Res 2010;3:9.
38. Lee J, Yun MJ, Nam KH, Chung WY, Soh EY, Park CS. Quality of life and effectiveness comparisons of thyroxine withdrawal, triiodothyronine withdrawal, and recombinant thyroid-stimulating hormone administration for low-dose radioiodine remnant ablation of differentiated thyroid carcinoma. Thyroid 2010;20:173-9.
39. Rosario PW, Xavier AC. Recombinant human thyroid stimulating hormone in thyroid remnant ablation with 1.1 GBq 131Iodine in low-risk patients. Am J Clin Oncol 2012;35:101-4.
40. Haymart MR, Banerjee M, Stewart AK, Koenig RJ, Birkmeyer JD, Griggs JJ. Use of radioactive iodine for thyroid cancer. JAMA 2011;306:721-8.
41. Mallick U, Harmer C, Hackshaw A, Moss L. Iodine or Not (IoN) for low-risk differentiated thyroid cancer; the next UK National Cancer Research Network randomised trial following HiLo. Clin Oncol (R Coll Radiol) 2012;24:159-61.